Biotech
4 biotech stocks that are ideal takeover targets
Speculation plays a big role when investing in biotech stocks, hence making them highly volatile. It could be after years…
Earnings preview: Will losses continue for Celsion in Q2
Celsion Corporation (NASDAQ: CLSN) is set to release its earnings results for the second quarter on Thursday before the market…
Progenics posts wider-than-expected loss in Q2
Progenics Pharmaceuticals (NASDAQ: PGNX) reported a wider loss in the second quarter due to higher costs and expenses despite a…
What to look for when Progenics Pharma posts Q2 earnings
Progenics Pharmaceuticals (NASDAQ: PGNX) is set to release its earnings results for the second quarter of 2019 on Friday before…
Is Advaxis exhausting its financial resources with the stock hitting a record low?
Advaxis Inc. (NASDAQ: ADXS) stock plunged to a record low of $1.54 on Tuesday as the late-stage biotech company has…
Cara Therapeutics Q1 loss widens but beats estimates
Cara Therapeutics Inc. (NASDAQ: CARA) reported a wider loss in the first quarter of 2019 due to higher costs and expenses.…
Biocept narrows loss in Q4
Biocept (BIOC) narrowed its loss in the fourth quarter, beating analyst estimates. However, sales failed to impress the street. Shares…
What is NASH and which biotech firms are vying for the first-mover status
NASH, or Nonalcoholic steatohepatitis, is undeniably a golden goose in the pharma space. The biggest corporate attraction towards this liver…